1. Home
  2. ACOG vs CDLX Comparison

ACOG vs CDLX Comparison

Compare ACOG & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.75

Market Cap

129.4M

Sector

N/A

ML Signal

HOLD

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

HOLD

Current Price

$0.67

Market Cap

69.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
CDLX
Founded
2000
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
129.4M
69.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
ACOG
CDLX
Price
$5.75
$0.67
Analyst Decision
Strong Buy
Hold
Analyst Count
1
3
Target Price
$18.00
$2.25
AVG Volume (30 Days)
70.5K
710.4K
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.13
EPS
N/A
N/A
Revenue
N/A
$233,273,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$132.35
$46.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.75
$0.67
52 Week High
$10.88
$3.28

Technical Indicators

Market Signals
Indicator
ACOG
CDLX
Relative Strength Index (RSI) 50.51 30.48
Support Level $5.16 N/A
Resistance Level $6.67 $1.04
Average True Range (ATR) 0.44 0.06
MACD -0.00 -0.01
Stochastic Oscillator 41.03 3.05

Price Performance

Historical Comparison
ACOG
CDLX

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About CDLX Cardlytics Inc.

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

Share on Social Networks: